Syndax Pharmaceuticals, Inc.
Financials
Valuation Metrics
Syndax Pharmaceuticals, Inc.'s Market Cap is $1.16B. At end of 2025 it was $1.82B. Ranked #2303 of 3,118 in US market (top 74%), #925 of 1,474 on NASDAQ (top 63%), #170 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.16B | US#2,303/3,118 Sec#170/265 |
| Revenue | $252M | US#2,486/3,118 Sec#102/265 |
| Net Income | $-221M | US—/3,118 Sec—/265 |
| Total Assets | $704M | US#2,617/3,118 Sec#130/265 |
| Net Assets | $15M | US#2,889/3,118 Sec#233/265 |
| Employees | 298 | US#2,408/3,118 Sec#110/265 |
| Value | ||
| P/B | 76.82x | US#2,889/3,118 Sec#231/265 |
| P/S | 4.60x | US#2,270/3,118 Sec#79/265 |
| FCF Yield | -19.04% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -31.37% | US#2,884/3,118 Sec#159/265 |
| Op. Margin | -77.05% | US#2,684/3,118 Sec#115/265 |
| Revenue Growth | 222.34% | US#48/3,118 Sec#19/265 |
| Financial Health | ||
| Debt Ratio | 4560.26% | US#2,895/3,118 Sec#238/265 |
| Total Debt | $589M | US#1,783/3,118 Sec#60/265 |
| FCF | $-221M | US#2,795/3,118 Sec#216/265 |
| Cash | $336M | US#1,334/3,118 Sec#75/265 |
| Current Ratio | 6.77x | US#363/3,118 Sec#113/265 |
| Performance | ||
| 1Y Return | -4.45% | US#1,758/3,118 Sec#143/265 |
| 1M Return | -25.63% | US#2,952/3,118 Sec#244/265 |
| From 52W High | -48.85% | US#2,540/3,118 Sec#190/265 |
| 1Y MDD | -48.71% | US#2,344/3,118 Sec#155/265 |
| Trading | ||
| Volume | 2,612,342 shares | US#918/3,118 Sec#85/265 |
| Trading Value | $35M | US#1,657/3,118 Sec#119/265 |
| Per Share | ||
| EPS | $-2.49 | US—/3,118 Sec—/265 |
| BPS | $0.17 | US#2,780/3,118 Sec#227/265 |
Company Info
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.